TALAPRO-2: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer
July 13th 2023Toni Choueiri, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent updates from TALAPRO-2, which studied talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer.
Understanding the Role of Clinical Trials in Renal Cell Carcinoma
May 30th 2018Toni K. Choueiri, MD, a medical oncologist at Dana-Farber Cancer Institute, discusses how clinical trials can help improve cancer treatments for patients with metastatic renal cell carcinoma, a largely incurable and lethal disease. He also shares recent statistics on the low clinical enrollment numbers as well as how many could potentially be enrolling for newer treatments.
Exploring the Combination of First-Line Avelumab/Axitinib in RCC
September 27th 2017Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses a phase 1b trial of first-line avelumab (Bavencio) plus axitinib (Inlyta) in patients with advanced renal cell carcinoma (RCC).